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The heavy chain IGHV1-69 germline gene exhibits a
high level of polymorphism and shows biased use
in protective antibody (Ab) responses to infections
and vaccines. It is also highly expressed in several
B cell malignancies and autoimmune diseases. G6
is an anti-idiotypic monoclonal Ab that selectively
binds to IGHV1-69 heavy chain germline gene 51p1
alleles that have been implicated in these Ab re-
sponses and disease processes. Here, we determine
the co-crystal structure of humanized G6 (hG6.3) in
complex with anti-influenza hemagglutinin stem-
directed broadly neutralizing Ab D80. The core
of the hG6.3 idiotope is a continuous string of
CDR-H2 residues starting with M53 and ending with
N58. G6 binding studies demonstrate the remarkable
breadth of binding to 51p1 IGHV1-69 Abs with
diverse CDR-H3, light chain, and antigen binding
specificities. These studies detail the broad expres-
sion of the G6 cross-reactive idiotype (CRI) that
further define its potential role in precision medicine.
INTRODUCTION
With the emerging field of precision medicine comes an expand-
ing need to understand immunoglobulin (IG)-biased gene utiliza-
tion at the molecular level so that vaccines with universal effi-
ciency in the population can be deployed. In the fields of
cancer and autoimmune disease, targeted immunotherapies
require knowledge of antibody (Ab)-protein interactions at theCell Repo
This is an open access article under the CC BY-Nmolecular level. Human immunoglobulin heavy-chain (IGHV)
polymorphisms are recognized as a rich source of humoral im-
mune system diversity, and the structural importance of the
heavy chain (VH) in binding interactions is well-established (Wat-
son et al., 2017). Structural and copy-number variations in many
IGHV loci can lead to wide variability in expression levels and
biological activity of Abs and B cell receptors (BCRs) (Avnir
et al., 2016; Watson and Breden, 2012; Watson et al., 2013).
Anti-idiotypic (anti-Id+) antibodies are defined as those
capable of binding to the variable domains of other Abs (idiot-
opes) (Grey et al., 1965; Kunkel et al., 1963; Oudin and Michel,
1969a, 1969b). In 1986, Mageed et al. (1986) generated mouse
anti-Id+ G6 by immunization with a human rheumatoid factor
(RF) Ab of the Wa group. G6 was shown to bind to the RF heavy
chain, not to the light chain. Through sequencing VH genes of
G6-reactive RFs (Newkirk et al., 1987) and G6-reactive CLL B
cells (Kipps et al., 1989), it became apparent that the G6 binding
idiotope is encoded by the 51p1 allele family of IGHV1-69 germ-
line genes (Kipps et al., 1989; Schroeder et al., 1987) that are
defined by CDR-H2 Phe54 (F-alleles) as opposed to the G6
nonreactive hv1263 germline gene alleles that encode CDR-H2
Leu54 (L-alleles) (Potter et al., 1999). Currently, the International
Immunogenetics Information System (IMGT) database lists 14
IGHV1-69 alleles, eight belong to the F-allele group and six to
the L-allele group that show remarkably variable distribution
across different ethnic populations (Avnir et al., 2016).
The expression of the G6 cross-reactive idiotype (CRI) is well-
studied (Charles et al., 2013; Potter et al., 1999). Sasso et al.
(1996) first reported that IGHV1-69 gene copy number correlates
with the frequency of tonsillar B cells positively stained with
G6; presence of G6-reactive cells in the mantle zones of
secondary B cell follicles may be strategic for host defense (Cer-
utti et al., 2013). In B cell chronic lymphocytic leukemia (B-CLL)rts 21, 3243–3255, December 12, 2017 ª 2017 The Authors. 3243
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. The G6 Idiotype Appears on Select Influenza sBnAbs
HV1-69-sBnAbs discovered in our previous study (Sui et al., 2009) were
analyzed by ELISA for binding to G6 (A). Their heavy chain CDRs sequences
are shown in (B) as well as other HV1-69-sBnAbs that were analyzed for G6
binding by using Biacore T100 (or by using Octet RED96 for CR9114 against
hG6.3). Grey colored residues are those that are in consensus with the
germline gene residues of IGHV1-69*01 (representative of 51p1 alleles). Also
shown are the residues at position 58, and the V-segment amino acid germline
identitymean and SDof theG6 reactive and nonreactive groups as determined
by IgBlast.(Chang et al., 2016) two distinct subgroups of patients are
defined based on the absence or presence of somatic mutations
in the variable regions of the IGHV genes (Fais et al., 1998; Hashi-
moto et al., 1995; Schroeder and Dighiero, 1994). Patients with
leukemic B cells encoding BCRs with unmutated VH genes
have a distinctly more aggressive and malignant disease with
much shorter survival rates (Damle et al., 1999) such as with
IGHV1-69 (Hamblin et al., 1999). Remarkably, the anti-Id+ G6
51p1 alleles are overwhelmingly predominant in this disease
(Johnson et al., 1997; Keating et al., 2003). Several other biased
F-allelic IGHV1-69 Ab responses and associations with disease
processes have been reported (Chan et al., 2001; Miklos et al.,
2000; Steininger et al., 2012; Tang et al., 2014; Yeung et al.,
2016; Ying et al., 2015). In influenza infection, the biased use of
IGHV1-69 F-alleles in the production and serum titers of
broadly neutralizing antibodies to the influenza A hemagglutinin
(HA) stem domain (HV1-69-sBnAbs) occurs (Avnir et al., 2014;
Pappas et al., 2014). Structurally, only the rearranged VH makes
contact with HA (Dreyfus et al., 2012; Ekiert et al., 2009; Sui et al.,
2009). Two influenza-related studies (Avnir et al., 2016; Wheatley
et al., 2015) specifically used G6 as a genotypic marker to
identify individuals who are devoid of F-alleles (i.e., L/L homozy-
gous) and showed that they have lower HV1-69-sBnAbs in
serum.
The unique anti-Id+ properties of G6 and its potential use in the
monitoring and treatment of IGHV1-69 Ab responses and associ-3244 Cell Reports 21, 3243–3255, December 12, 2017ated diseases, respectively, motivated us to comprehensively
study the G6 idiotope at the atomic level. In the present study,
the co-crystal structures of a potent humanizedG6, hG6.3 (Chang
et al., 2016), bound to HV1-69-sBnAb D80 (Sui et al., 2009), and
D80 alone are reported to 2.5 A˚ resolution. Detailed comparative
structural analysis permitted the determination of the hG6.3 idiot-
ope. Additional binding and modeling studies of a large panel of
G6-reactive Abs as well as HV1-69-sBnAbs and their variants
were performed. The G6 CRI is expressed on IGHV1-69 Abs
withwidely varyingCDR-H3, light chains and antigen specificities.
Remarkably, the G6CRI is lost on the majority of HV1-69-sBnAbs
due to critical mutations around the idiotope core at CDR-H2
Phe54 that are requisite for HA binding. These hG6.3 studies pro-
vide a precise delineation of the G6 CRI and a rationale for using
hG6.3 to monitor IGHV1-69 Ab responses to vaccination and
infection and advance anti-Id+-based immunotherapies.
RESULTS
Defining the G6 Idiotype on IGHV1-69-Encoded Human
Anti-influenza Abs Targeting the HA Stem Domain
We (Sui et al., 2009) and others (Corti et al., 2017; Pappas et al.,
2014) discovered the biased use of IGHV1-69 F-alleles in HV1-
69-sBnAbs. These data led us to further investigate if these
HV1-69-sBnAbs also bind to the anti-Id+ Ab G6. Surprisingly,
an ELISA assay showed that of the five previously discovered
HV1-69-sBnAbs (Sui et al., 2009), only D8 strongly bound to
G6 (Figure 1A). Very weak binding was also observed for the
IGHV1-2 germline-based sBnAb H40. In subsequent assays
that tested G6 binding of 7 other HV1-69-sBnAbs, only
CR6331 (Throsby et al., 2008) and 70-1F02 (Wrammert et al.,
2011) were found to express the G6 CRI. In addition, no binding
activity was observed when C9114 (Dreyfus et al., 2012) was
tested for binding against humanized hG6.3 (Chang et al.,
2016). Thus, of a total of 12 HV1-69-sBnAbs that were tested,
only three were G6-reactive. Analysis of the three G6-reactive
heavy chain CDR sequences (Figure 1B) revealed the common-
ality of P52aA/G substitution in CDR-H2 together with shorter
CDR-H3 regions that encode three tyrosine residues at positions
97–99 (Kabat numbering). The G6-reactive HV1-69-sBnAbs
maintained germline N58. Fewer amino acid substitutions occur
in CDR-H1 and CDR-H2, with higher V-segment germline gene
identity (92.0% ± 3.5%), for G6-reactive compared to the
G6-nonreactive HV1-69-sBnAbs (85.1% ± 1.5%).
Three of these G6-nonreactive HV1-69-sBnAbs, F10, A66,
and CR6261, were used to investigate the contributions of
V-segment amino acid substitutions, whereby the expression
of G6 idiotope was analyzed for chimeras constructed by
using the IGHV1-69 germline non-mutated V-segment and
maintaining the original (wild-type; WT) CDR-H3/J and light
chains. Restoration of strong G6 binding was observed for the
three VH1-69/F10, VH1-69/A66, and VH1-69/CR6261 chimeras
(Figure 2A) that now failed to bind HA (data not shown). This
finding of reciprocal gain of G6-idiotype with loss of HA binding
was unexpected. We have previously shown that a consensus
motif for HV1-69-sBnAbs is composed of critical amino acid
substitutions in the VH-segment together with a hydrophobic
amino acid at position 53, Phe54, and properly positioned
Figure 2. Analysis of G6 Idiotype by Using HV1-69-sBnAb Variants
(A) The V-segment of the non-G6 reactive HV1-69-sBnAbs F10, CR6261, and A66was replacedwith the non-mutated IGHV1-69*01 germline V-segment. Binding
kinetics of the three variants (VH1-69/F10, A66, CR6261) were analyzed against G6 by using Biacore T100.
(B) VH1-69/F10 variants were generated, in which F10’s V-segment amino acid substitutions were back-introduced and then analyzed by Biacore T100 for
binding activities against G6 when using a single concentration of 2.85 mg/mL per variant.
(C and D) The same variants were also tested for binding by using an artificial B cell receptor display system in which the VH1-69/F10 variants were displayed as
BCRs and either G6 (C) or hG6.3 (D) were added at the concentration of 50 mg/mL. In the upper panels of (C) and (D), the binding response is shown for isotype
controls and varying concentrations of G6 or h6.3 when tested against VH1-69/F10. Binding was monitored by fluorescent measurements of calcium ions being
released from intracellular compartments.
(E) The heavy chain of F10 is shown (PDB 3FKU) with residues colored in red that were back-introduced in the VH1-69/F10 variants and the unchanged CDR-H3/J
residues are shown in pink.CDR-H3 Tyr (Avnir et al., 2014). Thus, unique VH-segment sub-
stitutions, particularly those involving the CDR-H2 loop, are
involved in HA binding.
To further define the contribution of individual VH-segment
substitutions for G6 and HA binding, several VH1-69/F10 vari-
ants were tested in which amino acid substitutions were back-
introduced into CDR-H2 (Figures 2B and 2E). The substitutions
of either I52S or I53M resulted in lower G6 binding affinity, as
determined by faster dissociation rates, and the combined
I52S I53M substitutions resulted in a significant loss in binding
affinity. Interestingly, in contrast to our previous report (Avnir
et al., 2014) that showed that VH1-69/F10 CDR-H2 I52S restored
binding activity to HA, while VH1-69/F10 CDR-H2 I53M did not,
both constructs had a similar effect on diminishing G6 binding. In
addition, the VH1-69/F10 CDR-H1 G26E G27V CDR-H2 I52SI53M variant (that introduced two HV1-69-sBnAb amino acid
changes in CDR-H1) resulted in complete loss of G6 binding.
This set of VH1-69/F10 variants was also displayed using arti-
ficial BCRs and tested against G6 and hG6.3 as antigens. Both
G6 and hG6.3 were able to cross-link the various VH1-69/F10
variant BCRs (Figures 2C and 2D), but not the WT F10. In
contrast to the kinetic binding data (Figure 2B), the VH1-69/
F10 CDR-H2 I52S and VH1-69/F10 CDR-H2 I53M variants had
similar and modest increases in binding, respectively, compared
to VH1-69/F10, and the combination CDR-H2 and CDR-H1/H2
variants also maintained some level of G6 binding. This disparity
may be attributed to avidity in the BCR experimental system that
is generated by bivalent to bivalent interactions (Vauquelin and
Charlton, 2013). Thus, the G6 idiotope is exclusively located in
the VH segment and is most sensitive to amino acid changesCell Reports 21, 3243–3255, December 12, 2017 3245
Figure 3. The Angle of Approach and Inter-
molecular Interactions between D80 and
hG6.3
(A) The angle of approach between D80 and hG6.3,
measured between the planes defined by the cen-
ters of mass for the V and C domains and the 2-fold
pseudo-symmetry axis (orange and red dots) of the
Fab fragments. The planes are colored lighter to
darker for parallel to perpendicular relative to the
image plane. The two red dots are aligned in the
sight line (visual axis) in the last panel.
(B) The crystal structure of D80-hG6.3 Fab frag-
ments splayed open to view the residues at the
intermolecular interface. The residues are colored
on a rainbow scale from blue to red for increasing
van der Waals energy, hence warmer colors indicate
residues with the most contribution to the intermo-
lecular contacts.
(C) The intermolecular van der Waals contact energy
values of residues at the interface displayed as bar
graphs for hG6.3 Fab and D80 Fab.in CDR-H2 but can be further influenced by amino acid changes
in CDR-H1.
The Crystal Structures of the D80 Fab Fragment and the
D80-hG6.3 Fab Fragment Complex
The G6 idiotope was further elucidated at the structural level by
investigating the critical binding interactions of one of these HV1-
69-sBnAbs, D80 (that has a similar VH chain as D8 except for a
K23R substitution) that binds both HA and hG6.3. The crystal
structures of the Fab of D80 were determined for both D80 alone
and bound to the hG6.3 Fab, each to 2.5 A˚ resolution (Figure 3;
Table S1). Macro level view of the hG6.3-D80 complex shows
that the two Abs form an angle of 130 with respect to the3246 Cell Reports 21, 3243–3255, December 12, 2017length and height of the centroid planes
(Figure 3A). The binding interface between
D80 and hG6.3 has a total buried solvent-
accessible surface area of 900 A˚2 per bind-
ing partner. The two antibodies interact
with each other through their variable do-
mains, where the CDR loops in the VH
domain of D80 Fab directly interact with
their complementary CDR loops in the VH
and light chain (VL) domains of the hG6.3
Fab (Figure 3B).
Intermolecular Binding Interface
between D80 and hG6.3
To quantify the extent of interactions made
by the CDRs, the intermolecular van der
Waals (vdW) contact energies were calcu-
lated and mapped onto the structures of
D80 and hG6.3 (see the Supplemental
Experimental Procedures) (Figure 3B).
Among the CDRs of D80, CDR-H2 contrib-
utes the most to the binding interface with
the largest magnitude of total vdW contact
energy (–7.5, –30.9, and –7.0 kcal/mol forCDR-H1, -H2, and -H3, respectively), confirming that the
hG6.3 binding idiotope is primarily located on CDR-H2 (red res-
idues in Figure 3B, lower right). The residues that make the most
extensive contacts with hG6.3 are M53 and F54 in CDR-H2, and
at the edge, N58. The N58 side chain makes 3 intermolecular
hydrogen bonds that are part of a larger hydrogen bonding
network that stabilizes the bound complex across the interface
(Figure 4A). A substitution at this position to cause loss of these
hydrogen bonds would destabilize and likely disrupt the binding
interaction. In agreement with this observation, all 3 HV1-69-
sBnAbs that are G6-reactive have the germline N58. In contrast,
8 of the 9 G6-unreactive Abs have a substitution at position 58,
with 6 Abs containing an N58K substitution, CR9114 having
Figure 4. Position H58 N Has Extensive Interactions with hG6.3 but Not with HA
(A) D80 heavy chain Asn58 is involved in an extensive hydrogen bonding (black dashed lines) network in the D80-hG6.3 structure.
(B) Position H58 is located outside the CDR-H2 loop region, on a small beta strand following the loop and does not make any intermolecular interactions with the
HA epitope in the F10-HA crystal structure. Alignment of D80 crystal structure onto F10 indicates H58 N would not be involved in any contacts with HA.
(C) Aligning the CDR-H2 F54 in F10 structure (pink) onto D80 (green), residue H58 N is positioned too far from hG6.3 (purple) to retain any intermolecular in-
teractions across the interface due to a kink in the backbone caused by H57 P. In addition, H53 M has a side chain orientation incompatible with hG6.3’s H33 W
with the backbone shifting relative to D80 due to H52 P in F10.N58A and D7 an N58S substitution. None of these substitutions
would be able to retain the intermolecular side chain hydrogen
bonds. Only the G6-nonreactive F10 has germline N58, this
exception is discussed below. Additionally, D80 CDR-H2 resi-
dues G55 and T56 and CDR-H3 residues Y98 and Y99 also
significantly contribute to the packing between the two Abs (Fig-
ure 3C, right), followed by CDR-H1 residues T31 and S33 and the
framework residue E73.
In hG6.3, most of the intermolecular vdW interactions are
contributed by Y97 followed by W33 of the heavy chain and
F94, Y91, Q93, N32, and S30 of the light chain (Figures 3B and
3C, left). D80’s M53 and F54 form a ‘‘knuckle’’ that inserts into
a pocket with M53 and G55 extensively interacting with Y97
and W33 of the hG6.3 heavy chain and F94 packs against Y91
of the light chain. The pocket in hG6.3 where this ‘‘knuckle’’
inserts is not entirely filled by D80 and may play a role in the di-
versity of antibody binding to hG6.3. A volume of 32 A˚3, as calcu-
lated by POVME (Durrant et al., 2014), lined by hydrophobicatoms remains (Figure S1), indicating the pocket could accom-
modate other hydrophobic side chains.
In addition to the vdW contacts, which capture the surface-
surface packing and shape complementarity at the binding inter-
face, additional contributions by polar (hydrogen bonding) and
pi-stacking interactions were analyzed to define the full hG6.3
idiotope (Figure 5; Table S2). In CDR-H1, residues T31, S33,
and Y35 have side chain hydrogen bonds with VH residues
W33 and D56 of hG6.3 (Figure 5A). As with vdW contacts,
CDR-H2 of D80 contributes the most to the interactions with
hG6: the side chain of T52, T56, and N58 of D80 have hydrogen
bonds to the VL residues N32, S92, andQ93 of hG6.3. The back-
bone carbon of G55 in this loop is also involved in a pi-stacking
interaction with Y99 of hG6.3 (Figure 5B, inset). The only polar
CDR-H3 interaction is pi-stacking between VH Y99 and hG6.3
VL F94 (Figures 5C and 5D). This Tyr is part of the triple Tyr motif
(Y97–Y99) that participates in an extensive pi-stacking interac-
tion network involving CDR-H2, CDR-H3, and hG6.3 residuesCell Reports 21, 3243–3255, December 12, 2017 3247
Figure 5. Hydrogen Bonding and Pi-Stacking
Interactions between D80 and hG6.3
Hydrogen bonds (yellow dashes) between D80
(green sticks) and hG6.3 (purple surface) at the
binding interface displayed for (A) CDR-H1 and (B)
CDR-H2 (inset: pi-stacking between Y99H of hG6.3
and the backbone carbon of G55 in D80).
(C and D) CDR-H3 has no intermolecular hydrogen
bonds (C) but participates in (D) an extensive
pi-stacking (yellow dashes) interaction network
involving the CDR-H2 and CDR-H3 of D80 (green)
and hG6.3 (purple).F94 (VL) andW33 (VH) (Figure 5D). The VL of D80 alsomakes one
hydrogen bond from R96 to hG6.3 Q90 (Table S2). Taken
together, analysis of vdW, hydrogen bonding, and pi-stacking in-
teractions identify D80 residues that contribute to intermolecular
interactions with the G6 as CDR-H1 positions 31 and 33,
CDR-H2 positions 53–58, and CDR-H3 positions 97–99, with
the key positions of the idiotope located on CDR-H2.
Comparison of D80 Unbound and hG6.3-Bound
Structures
The overall unbound versus hG6.3-bound D80 structures do not
have anymajor backbone changes except a slight increase in the
angle between the VH and CH1 domains relative to each other
(1–3, Figures S2A–S2C), which may also be affected by crystal
packing, suggesting a lock-and-key type protein-protein bind-
ing. To compare the bound and unbound structures quantita-
tively, the distance difference matrix was calculated for the
heavy chain of D80 Fab fragment (Figures S2D–S2F; Supple-
mental Experimental Procedures). In accordance with the in-
crease in inter-domain angle, the majority of distance changes
correspond to increase in distance between residues in D80’s
VH and CH1 domains when bound to hG6.3. Within each domain
the changes were muchmore subtle, with themost considerable
changes in the CDR-H1 loop and a few residues displaying dis-
tance changes of more than 2 A˚ in CDR-H2 and CDR-H3 loops.
The pi-stacking interaction network described above (Figure 5D)
is conserved between the unbound and bound structures of D80
andmay contribute to stabilizing the loop structures in a binding-
competent state in the unbound form. Overall, the similarity of
CDR loops regardless of whether D80 is bound to hG6.3 or not
indicates that the epitope pre-exists in the unbound state and3248 Cell Reports 21, 3243–3255, December 12, 2017does not need to undergomajor conforma-
tional changes for binding to occur. Hence,
this similarity promises that the D80-hG6.3
crystal structure determined here can
serve as an appropriate template to model
the binding of other G6-reactive Abs for
which unbound structures are available.
Substituting CDR-H2 F54 or N58 Has
Differential Effects on hG6.3 and HA
Binding
F54L substitution in an IGHV1-69 F-allele
Ab has been shown (Potter et al., 1999) tocompletely abolished binding to G6. To test whether D80 F54
is critical for binding, an F54L variant was engineered and bind-
ing affinity was completely abolished (Figure 6A). Molecular
modeling of F54L on the hG6.3-D80 crystal structure (Figures
6C and 6D) predicted a substantial loss of intermolecular vdW
contacts. Specifically, F54 aromatic ring forms extensive vdW
contacts with hG6.3 light chain Y91. The smaller L54 would not
reach the Y91 CB atom and thus cannot form these interactions.
This decrease in vdW contacts may also affect the stability of the
extensive pi-stacking interaction network involving D80 CDR-H2
and CDR-H3 (Figure 5D). In addition, L54 substitution would
result in decrease of vdW contacts with light chain P96 and
heavy chain H35 and S95, amounting to a total predicted loss
of 5 kcal/mol in vdWcontact energy. Interestingly, while G6 bind-
ing is lost with the F54L substitution, equivalent binding is still
maintained against H5VN04 HA (Figure 6B). The similar binding
profile of D80 WT and D80 F54L to HA suggest that F54 in D80
does not have a critical role in HA binding and rather binding is
mainly mediated through CDR-H3 Y98 (Avnir et al., 2014). This
observation is also in agreement with the study by Pappas
et al. (2014) that somatic mutations in the VH-segment of HV1-
69-sBnAbs can compensate for the critical role of F54 in HA
binding.
In addition, substitutions at position 58 are detrimental to G6
binding, however, all the HV1-69-sBnAbs defined by substitu-
tions at position 58 (Figure 1) are still able to bind HA (except
of F10, discussed below). In the available crystal structure of
F10 bound to HA, the germline-encoded residue of N58 is
located on a beta strand following CDR-H2 and does not make
any hydrogen bonds or vdW contacts with HA (Sui et al.,
2009). Aligning the D80 Fab structure onto F10, N58 is located
Figure 6. Changing D80 F54L Abolished Binding to hG6.3 but Maintained Binding to H5VN04
(A) A D80 variant in which the CDR-H2 Phe54 was substituted with Leu54 (D80 F54L) did not show any binding activity to hG6.3 as analyzed by using an Octet
RED96 instrument.
(B) This variant, however, did retain strong binding activity against the H5VN04 HA.
(C and D) Focused view on D80 CDR-H2 colored blue to red for increasing vdW contact energy with hG6.3, containing Phe54 (left, red) in the crystal structure and
modeled Leu54 (right, yellow) (C), indicating that the vdW contacts would decrease with F54L substitution, primarily with (D) L91 Y and H35 H of hG6.3, and
amount to an overall reduction in vdW contact energy of 5 kcal/mol.in the same position in D80 with respect to HA and hence is not
involved in any intermolecular interactions (Figure 4B). Thus, the
difference in the epitope used by D80 in hG6.3 versus HA binding
explains why HV1-69-sBnAbs with a substitution at N58 can
retain HA binding despite becoming G6-unreactive.
Establishing Specificity of G6 Binding to IGHV1-69
F-Alleles through scFv-Phagemid Library Panning
The breadth of G6 reactivity for rearranged IGHV1-69 genes was
further investigated. An assay was developed in which our 27
billion-member Mehta I/II non-immune human Ab scFv-phage-
mid-Ab library was panned against beads coupled with G6
(Figure 7). DNA sequences from the phagemid-Abs recovered
from the beads confirmed that G6 is highly specific to IGHV1-69
F-allele group Abs (Figure 7A). Long-read PacBio next generation
sequencing of the pre-selected phagemid-Ab library confirmed
the G6-selected IGHV1-69 F-allele-encoded Abs was not due to
the biased Mehta I/II library composition or due to absence of
IGHV1-69 L-alleles (not shown). High diversity in the eluted Abs
was observed with respect to D-segments (Figure 7B), J-seg-
ments (Figure 7C), and CDR-H3 length (Figure 7E). Promiscuous
use of kappa and lambda light chains was also noted (Figure 7D).
A single noticeable difference in the D-segment usage between
the G6-selected and unselected Abs is that the former had only
one Ab comprised of the IGHD2-15*01 D-segment, which doesnot encode CDR-H3 Tyr’s in any reading frame, versus 8% in
the unselected Abs (Figure S3A).
V-segment analysis revealed preferential binding to non-
mutated V-segments (Figures 7F and S4). Our analyses reveal
a paucity of CDR-H2 amino acid substitutions (Figure 7G):
explicitly, of the 142 IGHV1-69*01 Abs, only 13 Abs had amino
acid substitutions in the CDR-H2 domain, while 36 Abs had
amino acid substitutions in the CDR-H1 domain (Figure S4).
This biased distribution of CDR-H1 versus CDR-H2 substitutions
is in line with the importance of germline CDR-H2 residues
mentioned above. In addition, none of the CDR-H2 substitutions
involved changes in F54, while analysis of CDR-H2 amino acid
sequences of 75 IGHV1-69 hv1263 allele-encoded Abs in the
pre-selected library showed that 8 had L54F substitutions, and
of these, none exhibited complete reversal to the F-allele 51p1
CDR-H2 sequence IIPIFGTA, thereby further demonstrating
the unlikelihood of G6 binding to hv1263 allele-encoded Abs
(Figure S3B).
G6 and hG6.3 Favor Binding to Antibodies Defined by
Non-mutated IGHV1-69 V- Segments
A subset of G6-reactive phagemid-Abs from the panning assays
with a range of V-segment mutations was chosen and analyzed
for their binding against both G6 and hG6.3 by ELISA assay that
utilized the Meso Scale Discovery (MSD) technology. The MSDCell Reports 21, 3243–3255, December 12, 2017 3249
Figure 7. Panning a Non-immune Human scFv Phagemid-Ab Library against G6
Human scFv phagemid-Ab display library was mixed with beads coupled with G6. After phagemid elution and bacterial infection, colonies were sequenced and
immunogenetic analysis was carried out.
(A–E) Each individual sequence represents one phagemid-Ab. (A) Of 197 sequences containing functional VH genes, 81%were composed of IGHV1-69 germline
gene and all IGHV1-69 sequences belonged to the F-allele group. Further analysis of the IGHV1-69 dataset points to high diversity in (B) D-segments, (C) J-
segment, (D) type of light chain, and in (E) CDR-H3 length.
(F) In contrast, analyzing the frequency of V-segment amino acids changes for the 142 IGHV1-69*01 Ab-sequences showed that G6 preferentially binds to Abs
characterized by non-mutated V-segments.
(G) The amino acid substitution diversity in the 142 IGHV1-69*01 Ab-sequences.signal obtained from four dilution points was used to calculate
area under the curve (AUC) values and these were tabulated in
Figure S5A. The majority of the IGHV1-69 phagemid-Abs (17 of
19) were defined by AUC values that were within or above one
SD of the mean (mean ± 1 SD = G6 8.91E + 05 ± 3.55E + 05;
hG6.3 6.80E + 05 ± 2.83E + 05). However, two Abs (S60 and
F66) encoding a germline CDR-H2 region had lower AUC values
than the mean minus one SD. Although, they did have 8 and 2
substitutions, respectively, in their V-segments inspection of
these two Abs against the panel of Abs that showed stronger
hG6.3 binding did not reveal an obvious cause for the weaker
binding (Figure S5B). In agreement with our previous report on
humanization of G6 (Chang et al., 2016), D80 hadweaker binding
activity against G6 and hG6.3 as defined by the AUC values of
1.67E + 05 and 7.83E + 04, respectively, and the three non-
IGHV1-69 phagemid-Abs exhibited only background binding3250 Cell Reports 21, 3243–3255, December 12, 2017activities that were defined by an average AUC of G6,
mean ± 1 SD = 3.68E + 03 ± 2.50 + 03; hG6.3, 2.69E + 03 ±
2.12E + 03. From these studies, we conclude that G6 shows
preferential binding for the germline CDR-H2 loop, and with a
few exceptions, does not show major differences between the
IGHV1-69 F-allele Abs despite variability in V-segment amino
acid substitutions, CDR-H3 composition, and type of light chain.
The Binding Conformation of IGHV1-69 Abs with Non-
mutated V-Segment against hG6.3 Based on the D80
Crystal Structure
The D80-hG6.3 structure was then used to model the binding of
IGHV1-69 Abs comprised of non-mutated V-segments. Two
51p1 IGHV1-69 Abs with germline V-segments and available un-
bound crystal structures, 1-69/B3 (Teplyakov et al., 2016), and
3B4 (Tu et al., 2016), were expressed as scFv-phagemid Abs
and were found to bind G6/hG6.3 stronger than D80 in MSD
ELISA assay (data not shown). The unbound structures were
aligned onto the D80 in the complex, followed by energy minimi-
zation (see the Experimental Procedures). The CDR-H2 in the re-
sulting G6-bound structures of both Abs superimpose very well
with D80 (Figure S6).Most importantly, 1-69/B3 and 3B4 are able
to maintain the critical interactions of F54 and N58 in CDR-H2
(Figures S6C and S6D). However, 3B4 and 1-69/B3 have more
extensive contacts with hG6.3 compared to D80, resulting in
more buried solvent accessible surface area upon binding
(1,400 A˚2; more than 50% compared to D80) and a correspond-
ing more than 50% increase in the intermolecular vdW interac-
tion energy. This increase is due to enhanced intermolecular in-
teractions of CDR-H3 as well as with VL, suggesting that while
the conformation of CDR-H2 is critical to G6 binding, further in-
teractions including those with CDR-H3 and the light chain can
enhance the binding strength of G6-reactive Abs.
HV1-69-sBnAb F10 Is G6-Unreactive Due to Prolines in
CDR-H2
Finally, to understand why HV1-69-sBnAb F10 is G6-unreactive
despite retaining the germline N58, binding of F10 to hG6.3 was
modeled using the D80-hG6.3 crystal structure as a template
(Figure 4C). When F10’s CDR-H2 is aligned onto the D80 struc-
ture to maintain the critical van der Waals contacts of the F54
side chain, N58 is positioned too far away from hG6.3 tomaintain
any of its three intermolecular hydrogen bonds (Figure 4; Table
S2). This displacement relative to the same position in D80 is
due to a kink in the beta strand following CDR-H2 caused by a
proline substitution at position 57 preceding N58. Thus, the pro-
line substitution at position 57 rigidifies CDR-H2 and creates a
kink in the backbone structure that renders F10 unable to simul-
taneously establish the key F54 and N58 interactions. In accor-
dance, none of the HV1-69-sBnAb with an A57P substitution in
our initial panel was G6 reactive (Figure 1B). However, mutation
of position 57 back to Ala in F10 was not sufficient to restore G6
reactivity (data not shown), most likely due to an I53M substitu-
tion next to a second proline in CDR-H2, the germline P52a. The
M53 side chain has a different conformation in F10 compared to
D80 and can be accommodated at the binding interface only in
the presence of a neighboring P52aG substitution that allows
backbone flexibility, as is the case in D80. Thus, G6 binding
can be lost in multiple ways, including due to a substitution of
the critical germline N58 itself, or a proline substitution at the pre-
ceding A57 that causes N58 to lose intermolecular interactions.
DISCUSSION
The anti-Id+ IGHV1-69 Ab G6 has been used extensively for over
30 years to characterize biologically important antibody pro-
cesses in humans. Since G6’s discovery, recognition of impor-
tant functions of IGHV polymorphism and related biased germ-
line gene usage in wellness and disease has grown, yet there
is a paucity of well-characterized anti-Id+ reagents that can be
used to monitor these serologic responses. In this study, an in-
depth investigation was conducted into the binding epitope of
the humanized version of G6, hG6.3 (Chang et al., 2016). We
solved the crystal structures of hG6.3 in complex with anti-influ-enza HV1-69-sBnAb D80, and D80 alone (Figure 3). The hG6.3
idiotope is centered around the CDR-H2 loop of D80, with
the M53 and F54 at the tip of this loop inserting into a
pocket in hG6.3, and the core of the idiotope extending to N58
(Figures 4 and 5) and interacting with both the heavy and light
chains of hG6.3 (Figure S7). G6 prefers binding to Abs for which
CDR-H2 is in the germline configuration (Figures 7, S4, and S5).
The anti-Id tolerates hydrophobic amino acid substitutions at po-
sition I53 (Figure S4); however, in striking contrast, the critical
role of germline F54 for binding is absolute. The germline
CDR-H2 boundary residue N58 (Figure 4), which participates in
an intermolecular hydrogen bonding network, also greatly con-
tributes to the binding energy. Maintaining the interactions of
both F54 and N58 simultaneously is required for binding G6
but not for HA binding where only the former is necessary. The
G6 idiotope also appears to require germline G55 as other side
chains would sterically clash with Tyr91 (Figures 1B, S4, and
S7B); however, this position is not invariant for HV1-69-sBnAbs
(Avnir et al., 2014). Small amino acid side chain substitutions of
T56V, T56A, and T56S are rarely found but larger side chains
are not seen and would be predicted to clash with hG6.3 light
chain residues (Figures S4 and S7). We conclude that the
hG6.3 angle of approach to the main core of the idiotope, which
is a continuous string of CDR-H2 residues starting with M53 and
ending with N58 is such that hG6.3 provides a hydrophobic
pocket lined between the heavy and light chains where M53
and F54 side chains are inserted, whereas the hG6.3 light chain
provides polar side chains (N32, S92, Q93) that form hydrogen
bonds to T56 and N58.
The binding interaction observed between hG6.3 and D80, in
which the D80 idiotope is not centered on the axis of the b-barrel
formed by the b strands of the VH and VL domains, is unusual but
not unprecedented. Co-crystallographic studies of human IgM
RF-AN bound to IgG4 Fc showed that the Ab residues involved
in autorecognition are all located at the edge of the conventional
combining site surface, leaving much of the RF light chain CDRs
(CDR-L1, -L2, and -L3) potentially available for recognition of a
different antigen (Corper et al., 1997). hG6.3 binding to D80 re-
sults in the hG6.3 heavy chain covering the apex of the D80
heavy chain and the hG6.3 light chain is positioned in front of
the D80 heavy chain-light chain interface. This topography of
interaction results in the notable lack of any contribution from
D80 CDR-L1 and -L2 to hG6.3 binding (Figure 3C). Whether
this remaining D80 VL surface area could be available for binding
another antigen is unknown but would require a narrow angle of
approach that does not rely on the main CDR loops of D80.
Because D80 utilizes the IGKV3-20 light chain germline gene,
this could be tested experimentally with anti-IGKV3-20 idiotypic
Abs or antigens that show biased binding of this light chain (de
Re et al., 2009). A similar hypothesis could be made for any of
the Id+ IGHV1-69 Abs that are recognized by G6.
The results from the G6 panning studies (Figure 7) demon-
strate the remarkable breadth of binding to the family of 51p1
IGHV1-69 Abs. The hG6.3:D80 co-crystal structure shows that
the pocket in hG6.3 is not entirely filled by D80, but could play
a role in the diversity of antibody binding (Figure S1). A wide va-
riety of CDR-H3 compositions with varying length and amino
acid substitutions are tolerated (Figures 7 and S4). The crystalCell Reports 21, 3243–3255, December 12, 2017 3251
structure demonstrates that hG6.3 primarily makes contact with
the D80 heavy chain, which is in agreement with the broad range
of light chain pairing that is seen from our G6 panning studies.
Soluble VH1-69/F10 VH domains also bind G6 with even higher
affinity than VH1-69/F10 scFvs that may be due to an increase in
buried surface area and contacts with CDR-H3 (Figure 3B and
data not shown). Many CDR-H1 substitutions appear to be
well-tolerated, as are substitutions in FR1-3 and CDR-H4 (Avnir
et al., 2014; Sela-Culang et al., 2013) in contrast to the paucity of
CDR-H2 amino acid substitutions that forms the core of the G6
idiotope (Figure S4). In agreement with the lack of G6 binding
to hv1263 encoding IGHV1-69 Abs, modeling of L54 in the
hG6.3/D80 complex structure suggests substantial losses in
vdW contact likely destabilizes the intermolecular interface
with hG6.3 (Figure 6). Thus, the highly specific yet broad range
of binding activities of G6 represents a unique property that
has not been described for other anti-Id+ Abs.
We further defined the structural features of the 51p1 alleles
that would lead to a loss of the G6 idiotope but retention of HA
binding and vice versa. The HV1-69-sBnAb family is defined,
at least in part, by critical amino acid substitutions in the VH
segment including germline CDR-H2 (II52P52aI53F54GTA) at posi-
tions I52 or P52a together with triad of a hydrophobic amino acid
at position 53, Phe54, and properly positioned CDR-H3 Tyr
(Avnir et al., 2014). The majority of tested HV1-69-sBnAbs did
not bind to G6 despite the fact that all were comprised of the
IGHV1-69 51p1 group (Figure 1A) and encode CDR-H2 F54
(Potter et al., 1999). The three G6-reactive HV1-69 sBnAbs had
the common features of P52aA/G substitutions, I53V/M hydro-
phobic substitutions, and a triplet of CDR-H3 Tyrs (Avnir et al.,
2014). The triple tyrosine motif in D80 is involved in an extensive
pi-stacking interaction network that may pre-organize the bind-
ing epitope and promote tight binding to G6 and HA (Figure 5);
related tyrosine pi-stacking interactions may also be involved
in 70-1F02 andCR6331 binding to both G6 andHA. Interestingly,
the chimeric VH1-69/F10 CDR-H2 I52S and I53M variants bind
with decreased affinity with respect to G6 compared to VH1-
69/F10 (Figure 2B), while the VH1-69/F10 CDR-H2 I52S variant
is capable of binding to HA, but VH1-69/F10 and VH1-69/F10
CDR-H2 I53M do not (Avnir et al., 2014). The flexible CDR-H2
residues introduced by the P52aA/G substitutions together
with germline A57 may increase CDR-H2 loop flexibility and
are features of the G6 Id+ HV1-69-sBnAbs whereas many of
the G6 non-reactive HV1-69-sBnAbs contain proline at these po-
sitions. G6 binding can be lost in multiple ways, including due to
a substitution of the critical germline N58 itself, or a proline sub-
stitution at the preceding A57 that causes N58 to lose intermo-
lecular interactions. These results suggest HV1-69-sBnAbs are
highly sensitive to structural variation around the core F54 con-
tact residue that appear to greatly affect the conformation of
the CDR-H2 loop with respect to optimal binding for HA and
G6 idiotope expression.
In conclusion, the growing recognition that IGHV polymor-
phism and biased VH germline gene usage are important,
albeit understudied, features of the Ab response in health and
disease is reshaping our thinking on how this knowledge can
be applied to precision medicine. In the area of host defense,
hG6.3 could be used to monitor the loss of G6 CRI in the circu-3252 Cell Reports 21, 3243–3255, December 12, 2017lating IGHV1-69 Ab pool as B cells evolve to become memory B
cells and HV1-69-sBnAbs secreting plasma cells in response to
seasonal (Corti et al., 2010) and emerging HA-stem derived ‘‘uni-
versal’’ influenza vaccines (Krammer, 2015). The G6 CRI may
also be useful for monitoring B cells and Abs that bind to and
neutralize HCV and MERS-CoV, respectively (Chan et al.,
2001; Tang et al., 2014; Ying et al., 2015). In the emerging field
of oncoimmunology, the high presence of G6 CRI on unmutated
BCRs seen in IGVH1-69-encoded B-CLL (Chang et al., 2016;
Hamblin et al., 1999), and the recognition of other IGHV1-69 dis-
orders involving pathophysiologic B cell expansions (Chan et al.,
2001; Miklos et al., 2000) could provide an avenue of therapeutic
intervention through hG6.3-mediated immune clearance. In
addition, hG6.3-based idiotype mapping (Idio-Seq) could add
an important new dimension to the field of immune recognition
where advances in the high-throughput sequencing and analysis
of expressed Ab repertoires (BCR-seq) in peripheral blood B
cells and LC-MS/MS proteomic spectrotyping of antigen-spe-
cific Abs (IG-seq) allow us to characterize, with unparalleled
accuracy, the serological repertoire to each of the Ab compo-
nents (Lee et al., 2016). This knowledge will aid in our under-
standing of how the serological repertoire changes in response
to vaccination, infection, cancer, and auto-immune diseases.
Defining the expressed G6 CRI repertoire and understanding
how Abs encoding a IGHV1-69 VH segment germline configura-
tion participate in wellness and pathologic humoral responses
(Watson et al., 2017) could be important part of this ongoing
paradigm shift.
EXPERIMENTAL PROCEDURES
Sequence Analysis of Abs
Abs were numbered according to the Kabat numbering scheme. CDR-H1, H2
are defined according to IMGT’s definitions. For CDR-H3, residues are shown
from Cys92 to Trp103 and for CDR-H3/J residues are shown from Cys92 to
Ser113. CDR-H4 was defined based on our previous study (Avnir et al.,
2014). Ab sequences were analyzed by using either IgBlast (Ye et al., 2013)
or IMGT/HighV-QUEST (Alamyar et al., 2012).
Construction and Expression of HV1-69-sBnAbs Variants
The HV1-69-sBnAbs variants were constructed and expressed as scFv as
described in Avnir et al. (2014). The original (WT) CDR-H3s and light chains
were maintained in all analyzed HV1-69-sBnAbs variants.
Binding Assays of HV1-69-sBnAbs to G6 and hG6.3
For Abs F10, A66, G17, D7, D8 and H40, standard ELISA assay was per-
formed by coating MaxiSorp plates with G6, adding HV1-69-sBnAbs in the
scFv-Fc format, and detecting bound HV1-69-sBnAbs with anti-human Fc
conjugated with HRP. For the IgG Abs 1009-3E06, 1009-3B05, 70-5B03,
and 70-1F02 (Wrammert et al., 2011) and for scFvs CR6331 and CR6261
(Throsby et al., 2008) a Biacore T100 instrument was used in which the
Abs were flowed over a CM5 chip that was immobilized with an anti-
mouse-Ab and captured G6. For C9114 scFv-Fc an Octet RED96 instrument
was used in which biotylinated-hG6.3 was captured on streptavidin sensor
after which the sensor was moved to a well containing the scFv-Fc
CR9114 Ab.
Binding Kinetics Assay of HV1-69-sBnAb Germline Variants
Biacore T100 single cycle kinetics assays were performed for VH1-69/F10,
VH1-69/A66, and VH1-69/CR6261 scFvs by using a CM5 chip that was
immobilized with an anti-mouse-Ab and captured G6 at a level of 320
response units (RUs). Similarly, the various VH1-69/F10 variants were
analyzed for G6 binding when each variant was used at a single concentra-
tion of 2.85 mg/mL.
B Cell Receptor Cross Linking Assay
The heavy chain and light chains of the various VH1-69/F10 variants were
cloned into a B cell receptor vector and the B cell cross linking assays with
G6 or hG6.3 were executed as described previously (Hoot et al., 2013) and
as detailed in the Figure 2 legend.
Protein Expression, Purification, and Crystallization
For crystallographic purposes, Fab fragments were expressed in insect cells
using a baculovirus expression system. Fab fragments were purified using a
polyhistidine tag with nickel-affinity chromatography and subsequent size
exclusion chromatography. For unbound D80 crystallization, the D80 Fab frag-
ment crystals were grown at 20Cby hanging-drop vapor diffusion in a solution
using 20% PEG 4000, 0.2 M CaCl2, and 0.1 M Tris pH 8.4. D80 crystallized in a
P 212121 space group with 2 molecules in the asymmetric unit and unit cell di-
mensions of a = 89.0, b = 91.6, and c = 106.8 A˚. For D80-G6 complex crystal-
lization, the D80-G6 Fab fragment complex crystals were grown at 20C by
hanging-drop vapor diffusion in a solution using 0.1 M NH4SO4 and 12%
PEG 3350. The D80-G6 complex was crystallized in a C 1 2 1 space group
with 1 molecule in the asymmetric unit and unit cell dimensions of a = 143.2,
b = 50.8, and c = 139.7 A˚.
Diffraction Data Collection and Structure Solution
Diffraction data was collected at cryogenic temperatures using synchrotron
radiation at the GM/CA-CAT 23-ID-B beam line at the Argonne National Lab-
oratory (Advanced Photon Source, Chicago, IL). Data was indexed and scaled
using xia2 and HKL3000 (Collaborative Computational Project, Number 4,
1994; Kabsch, 2010; Minor et al., 2006; Winter et al., 2013). Molecular replace-
ment solutions were determined using M-RAGE in PHENIX (Adams et al.,
2010; Bunko´czi et al., 2013). Cycles of rigid body, restrained, and TLS refine-
ment with subsequent model building were performed using phenix.refine in
PHENIX and Coot, respectively (Adams et al., 2010; Emsley et al., 2010).
Binding Assays of the D80 F54L Variant
Mutagenesis of D80 F54 scFv-Fc to D80 L54 scFv-Fc was achieved using
QuikChange Lightning kit according to manufacturer’s protocol. Binding
assays were performed using the Octet RED96 instrument with streptavidin
sensors. Biotinylated hG6.3 or biotinylated hemagglutinin H5VN04 (H5
A/VietNam/1203/04) were loaded at a concentration of 0.5 mg/mL, and the
various analyzed Abs were used at a concentration of 10 mg/mL.
Panning the Naive Human scFv Phagemid Library against Beads
Coupled with G6
Magnetic M-280 Tosylactivated DynaBeads were coupled with an isotype
control mouse Ab and with G6 according to the manufacturer’s protocol.
The Mehta I/II phagemid library mixture was subtracted of non-specific and
mouse-IgG binders by performing two rounds of subtractions with the isotype
control beads after which the phagemid suspension was added to G6 coupled
beads. Following six washes with TBS-Tween-20, the phagemids were eluted
with 100 mM of TEA and neutralized with PBS. The eluted phagemid suspen-
sion was used to infect TG1 cells from which single clones were sequenced.
The results of Figures 7 and S4were obtained from several G6 panning assays.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the atomic coordinates for the crystal structures of
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